Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based Ajinomoto and Astellas Pharma have announced the approval for an additional indication for Fastic or Starsis tablet, a fast-acting postprandial hypoglycemic agent, jointly developed by the two companies for use in combination therapy with thiazolidines.
Subscribe to our email newsletter
The newly approved combination therapy between Fastic or Starsis tablet (nateglinide) that suppresses elevation of postprandial blood glucose levels and thiazolidines that improve insulin resistance has already been proven to be effective and safe in the US, the two companies said.
The two companies conducted clinical trials on Japanese patients for the combination therapy with thiazolidines and obtained the approval for the indication. Through this approval, nateglinide is expected to provide a new choice of effective therapeutic methods for type 2 diabetic patients in Japan.
Nateglinide, an amino acid derivative, is an oral hypoglycemic agent that has insulin secretion enhancing effect with quick onset and short duration.